Arecor Therapeutics Plc (6UI)

Overview

Arecor Therapeutics plc operates as a biopharmaceutical company in the United Kingdom, primarily focusing on the development of products targeting diabetes and other medical conditions. Utilizing its proprietary reformulation technology platform, Arestat, the company is actively working on creating a portfolio of proprietary products to address the needs of patients with diabetes and other indications. Additionally, Arecor collaborates with various pharmaceutical and biotechnology companies to enhance the reformulations of existing therapeutic products. Since its establishment in 2007, Arecor Therapeutics plc has been committed to innovation in medication reformulation and delivery, aiming to improve patient outcomes and quality of life. The company is headquartered in Little Chesterford, the United Kingdom, underscoring its significant role in the UK's biopharmaceutical landscape.

Products and Services

• Ogluo:

Ogluo is an innovative product offered by Arecor Therapeutics plc, designed to treat severe hypoglycaemia events in patients with diabetes. This critical emergency solution addresses a significant need within the diabetes care spectrum, providing a vital resource for managing acute hypoglycemic episodes effectively.

• AT247:

AT247 is an advanced ultra-rapid acting insulin currently in Phase 1 development. Aimed at improving the management of both Type I and Type II diabetes, AT247 represents a significant advancement in insulin therapy. By accelerating the absorption of insulin post-injection, this formulation seeks to more closely mimic the natural insulin release of the body, potentially improving glycaemic control and enhancing patient quality of life.

• AT278:

Another innovative product in Arecor's pipeline is AT278, an ultra-concentrated rapid acting insulin formulation. Targeting the challenges of diabetes management, AT278 is designed to accelerate insulin absorption following injection, offering a more efficient and effective means of controlling blood glucose levels. This formulation has the potential to significantly benefit diabetics who require higher doses of insulin or seek a more convenient and discreet dosing regimen.

• Collaboration with TRx Biosciences Limited:

Arecor is also engaging in a promising research collaboration with TRx Biosciences Limited. This partnership focuses on the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product. Such an advancement could revolutionize diabetes treatment by offering a non-injectable option for GLP-1 therapy, increasing patient compliance and improving therapeutic outcomes.

• Collaboration with Medtronic plc:

The collaboration with Medtronic plc aims to develop a novel thermostable insulin for implantable pump delivery. This initiative seeks to enhance the convenience and efficacy of continuous insulin delivery systems, potentially transforming the treatment landscape for patients requiring constant insulin administration.